Dr Jitendra Singh dedicates India’s first public-funded DST-ICGEB ‘Bio-Foundry’

IMT News Desk
IMT News Desk
· 2 min read

The facility will serve as a platform for scaling up bio-based innovations in collaboration with startups and researchers

Addressing the International Centre for Genetic Engineering and Biotechnology (ICGEB) Board Meeting of Governors in New Delhi, Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science & Technology, Minister of State (Independent Charge) for Earth Sciences, MoS PMO, Department of Atomic Energy and Department of Space, MoS Personnel, Public Grievances and Pensions described India as the emerging global biotech destination and said, this is the most appropriate venue for such deliberations at a time when India has much to contribute to the world community.

The meeting was attended by representatives from more than 60 countries.

On the occasion, the minister dedicated India’s first-of-its-kind public-funded DST-ICGEB ‘Bio-foundry’ at the 31st Board Meeting of Governors of the International Centre for Genetic Engineering and Biotechnology (ICGEB) in New Delhi.

Dr Singh expressed pride in ICGEB New Delhi’s pioneering role in implementing the BioE3 Policy, especially through the newly dedicated Bio-foundry. The facility will serve as a platform for scaling up bio-based innovations in collaboration with startups and researchers.

ICGEB has 69 member countries and plays a key role in biotechnology-led sustainable global development through research, training, and technology transfer.

The ICGEB Board was represented by Dr Jelena Begovic, President, ICGEB Board of Governors, who underscored the critical importance of biotechnology in addressing the needs of today’s rapidly changing world.

Dr Lawrence Banks, Director General of ICGEB (Italy), lauded India’s exceptional commitment and impressive strides in the biotech sector.

Marianna Maculan, Secretary of the ICGEB Board of Governors, was also present during the proceedings.

Dr Rajesh Gokhale, Secretary of the Department of Biotechnology (DBT), highlighted India’s growing leadership in the biomedical and bio-industrial sectors, emphasising recent initiatives that are shaping the future of these domains. Dr Alka Sharma, Senior Adviser at DBT and Dr Ramesh Sonti, Director, ICGEB were also present at the 31st Board Meeting.

PIB

Read Next

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director
News
July 14, 2026

PM Modi to Dedicate Key Healthcare Infrastructure Projects to Nation on July 17: PGIMER Director

Prime Minister Narendra Modi will dedicate several key healthcare infrastructure projects to the nation on July 17, according to PGIMER Director Dr Vivek Lal. The projects include the Advanced Mother and Child Centre, the Advanced Neurosciences Centre and a new Critical Care Block, all of which are expected to strengthen tertiary care services and expand […]
Article by: IMT News Desk
OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars
News
July 14, 2026

OneSource Specialty Pharma and Formycon AG Announce Strategic Manufacturing Partnership for Biosimilars

OneSource Specialty Pharma Limited and Formycon AG have announced a strategic manufacturing partnership for biosimilars, bringing together Formycon’s biosimilar development expertise and OneSource’s integrated biologics manufacturing capabilities to support global markets. Under the agreement, OneSource will serve as a strategic manufacturing partner for Formycon and provide both drug substance and drug product manufacturing from its […]
Article by: IMT News Desk
FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi
News
July 14, 2026

FDA Approves At-Home Starter Dose of Eisai-Biogen’s Alzheimer’s Drug Leqembi

The U.S. Food and Drug Administration has approved an at-home starting dose of Eisai and Biogen’s Alzheimer’s drug Leqembi, allowing some patients to begin treatment with injections administered by themselves or a caregiver. The decision expands access to the drug’s subcutaneous formulation, which can now be used as a starter dose rather than only after […]
Article by: IMT News Desk
Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition
News
July 14, 2026

Emcure Pharmaceuticals Consolidates Full Ownership of Gennova Amid Leadership Transition

Emcure Pharmaceuticals Limited has announced the consolidation of its shareholding in biopharma subsidiary Gennova Biopharmaceuticals Limited, alongside a leadership transition, as it sharpens its focus on biologics and biosimilars. The company is acquiring the entire 12.05% minority stake in Gennova held by Dr Sanjay Singh and others, taking its ownership to 100% and making Gennova […]
Article by: IMT News Desk